Breaking News

German November IFO Confidence at 104.7; Median Forecast 103.0
Tweet TWEET

RBCC Partner Therakine Presents Novel Drug Delivery Technology at Biotech Showcase

  RBCC Partner Therakine Presents Novel Drug Delivery Technology at Biotech   Showcase  Biotech Showcase 2014  Business Wire  MIRAMAR BEACH, Fla. -- January 15, 2014  Rainbow Coral Corp. (OTCBB: RBCC) joint venture partner Therakine, Ltd., presented its new novel drug-delivery technology at one of the world’s largest and most important gatherings of life sciences investors this week at the Biotech Showcase in San Francisco.  RBCC is partnering with Therakine to market and develop a revolutionary new injectable, sustained-release technology poised to vastly improve patients’ use of a crucial drug in the fight against drug and alcohol dependence. The joint venture plans to soon offer the only intramuscular, programmable release of the powerful opioid receptor antagonist Naltrexone available anywhere in the $142.5 billion drug delivery industry.  This week’s Showcase presentation could go a long way toward making the product’s successful launch a reality.  “We’re extremely thrilled with the response we’ve received from attendees,” said RBCC CEO Kimberly Palmer. “We’re already discussing the development of new drug delivery programs using this same innovative protocol produced by Therakine. I expect to begin talks soon with more potential partners that are well-positioned to capitalize on this technological breakthrough.  “The future of this protocol is extraordinarily promising, and it has a lot of people excited,” she continued.  Phase II of development on the drug-delivery tech is currently underway, focusing on micronization of the technology as well as extension of its sustained release time.  RBCC's biotech division, Rainbow BioSciences, is working with partners such as Therakine to capitalize on the incredible growth of the global drug delivery market by delivering new medical and research technology innovations in order to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Valeant Pharmaceuticals International (NYSE: VRX).  For more information on RBCC’s other biotech initiatives, please visitwww.rainbowbiosciences.com/investors.html.  About Rainbow Biosciences  Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visitwww.RainbowBioSciences.com.  Notice Regarding Forward-Looking Statements  Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.  Contact:  Rainbow Coral Corp. Kimberly Palmer, 850-269-7230 President and CEO info@rainbowcoral.com  
Press spacebar to pause and continue. Press esc to stop.